False-positive serum prostate-specific antigen values in a patient with non-Hodgkin lymphoma of the kidney

Urology. 1995 May;45(5):875-8. doi: 10.1016/S0090-4295(99)80099-5.

Abstract

Prostate-specific antigen (PSA) is the clinically most useful tumor marker for prostate cancer. Although false-positive elevations have been reported due to disease processes outside the prostate gland with the use of the polyclonal assay, such false-positive test results have been exceedingly rare with the use of the monoclonal assay. We report the case of a patient diagnosed with a B-cell lymphoma of the kidney and a significant elevation of serum PSA levels by monoclonal assay in the absence of either inflammatory or malignant prostate disease. PSA returned to normal during lymphoma-specific chemotherapy with a cyclophosphamide, mechlorethamine, vincristine, procarbazine, prednisone regimen. Possible explanations and clinical implications are discussed.

Publication types

  • Case Reports

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • False Positive Reactions
  • Humans
  • Kidney Neoplasms / blood
  • Kidney Neoplasms / diagnosis*
  • Kidney Neoplasms / drug therapy
  • Lymphoma, B-Cell / blood
  • Lymphoma, B-Cell / diagnosis*
  • Lymphoma, B-Cell / drug therapy
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prostate-Specific Antigen / blood*
  • Tomography, X-Ray Computed

Substances

  • Prostate-Specific Antigen